Related Experiment Video
Updated: Jun 20, 2026
Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
Published on: March 12, 2018
Abciximab: a reappraisal of its use in coronary care
Marco Valgimigli1, Gianluca Campo, Matteo Tebaldi
1Cardiovascular Institute, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy and Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago (BS), Italy.
Insights
Glycoprotein (GP) IIb/IIIa inhibitors, like abciximab, are potent antiplatelet agents crucial for managing acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI). Abciximab demonstrates significant efficacy in reducing ischemic events, even with clopidogrel pre-treatment.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Platelet reactivity is central to ischemic events in acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI).
- Glycoprotein (GP) IIb/IIIa inhibitors represent the most potent class of antiplatelet agents.
- Abciximab is a widely studied GP IIb/IIIa inhibitor with a unique mechanism of action.
Purpose of the Study:
- To review the clinical efficacy and applications of abciximab in managing ischemic adverse events.
- To highlight abciximab's role in patients undergoing PCI, including those pre-treated with clopidogrel.
- To explore novel applications of abciximab, such as in drug-eluting stents.
Main Methods:
- Review of clinical trial data (EPIC, EPISTENT, EPILOG, ISAR-REACT 2).
- Analysis of abciximab's pharmacokinetic and pharmacodynamic properties.
- Examination of studies involving abciximab-coated stents and intracoronary administration.
Main Results:
- Abciximab administration before PCI significantly reduces acute ischemic complications compared to placebo.
- In non-ST-segment elevation ACS patients, abciximab reduces adverse events despite optimal clopidogrel pre-treatment.
- Abciximab-coated stents and intracoronary use show promising results for future clinical applications.
Conclusions:
- Abciximab is a highly effective GP IIb/IIIa inhibitor for preventing ischemic events in ACS and PCI.
- Its utility is confirmed even in combination with other antiplatelet agents like clopidogrel.
- Emerging applications suggest a potentially expanded role for abciximab in cardiovascular interventions.
Abstract:
Platelet reactivity plays a pivotal role in the pathogenesis of ischemic adverse events during and after acute coronary syndromes (ACS), and percutaneous coronary intervention (PCI). Glycoprotein (GP) IIb/IIIa inhibitors are the strongest antiplatelet agents currently available on the market and three different compounds, namely abciximab, tirofiban, and eptifibatide, have been approved for clinical use. Abciximab has been investigated in the clinical field far more extensively than the other GPIIb/IIIa inhibitors. Abciximab is an anti-integrin Fab fragment of a human - mouse chimeric monoclonal antibody with high affinity and a slow dissociation rate from the GP IIb/IIIa platelet receptor. Abciximab, given shortly before the coronary intervention, is superior to placebo in reducing the acute risk of ischemic complications (EPIC, EPISTENT, EPILOG trials); moreover, in the ISAR-REACT 2 study abciximab has been shown to reduce the risk of adverse events in patients with non ST-segment elevation ACS who are undergoing PCI even after optimal pre-treatment with 600 mg of clopidogrel. Finally, abciximab has been also used in abciximab-coated stent, with only bolus administration regimen and for direct intracoronary use with promising results that may extend and/or modify its current use in clinical practice in future.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction
01:26Acute Coronary Syndrome V: Nursing Management
01:21Rheumatic Heart Disease III: Medical Management